Cardiovascular disease and lipids: Issues and evidence for the management of dyslipidaemia in primary care

European Journal of General Practice

Volumn 9, Issue 1, 2003, Pages 16-24

  Hobbs, F D Richard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cardiovascular disease; Lipids; Prevention; Primary care; Risk factors

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; BEZAFIBRATE; BILE ACID; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RESIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; EVIDENCE BASED MEDICINE; FATIGUE; FLATULENCE; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; LOW DRUG DOSE; META ANALYSIS; MYOSITIS; NAUSEA; PATIENT CARE; PRACTICE GUIDELINE; PREDICTION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; STOMACH DISTENSION; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037345137     PISSN: 13814788     EISSN: None     Source Type: Journal    
DOI: 10.3109/13814780309160389     Document Type: Review

References (61)

1. Murray CJ, Lopez AD. The global burden of disease, 1990-2020. Nat Med 1998;4(11):1241-3.
2. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mähönen M, Cepaitis Z, Kuulasmaa K, et al. for the WHO MONICA Project. Estimation of contribution of changes in coronary care to improving survival, event rates and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000;355:688-700.
3. Gillum RF. Heart and stroke facts. Am Heart J 1993;126:1042-7.
4. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994;13(Suppl4):S107-12.
5. McMurray J, Hart W, Rhodes G. An evaluation of the cost of chronic heart failure to the National Health Service in the UK. Br J Med Econ 1993;6:99-110.
6. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18(10):1569-82.
7. Department of Health. National Service Framework for Coronary Heart Disease. London: HMSO, 2000.
8. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
9. Hobbs FDR, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: The Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002;19(6):596-604.
10. Peters TJ, Montgomery AA, Fahey T. How accurately do primary health care professionals use cardiovascular risk tables in the management of hypertension? Br J Gen Pract 1999;49:987-8.
11. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995;310:975-8.
12. Hippisley-Cox J, Pringle M. General practice workload implications of the national service framework for coronary heart disease: Cross sectional survey. BMJ 2001;323:269-70.
13. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):S1-9.
14. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152(7):1490-500.
15. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
16. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7.
17. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events Trial (CARE) investigators. N Engl J Med 1996;335(14):1001-9.
18. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339(19):1349-57.
19. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615-22.
20. Pitt B, Waters D, Brown WV, Van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment (AVERT) Investigators. N Engl J Med 1999;341(2):70-6.
21. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. Circulation 1999;99(2):216-23.
22. White HD, Simes RJ, Watson J. Treatment with pravastatin reduces the risk of stroke in patients with coronary heart disease and average cholesterol levels: The LIPID trial. Eur J Neurology 1998;5(Suppl 3):10.
23. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92(7):1758-64.
24. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-88.
25. Kannel WB. Contribution of the Framingham Study to preventive cardiology. J Am Coll Cardiol 1990;15:206-11.
26. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70(7):733-7.
27. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79(1):8-15.
28. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317(20):1237-45.
29. Rubins HD, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) Study Group. N Engl J Med 1999;341(6):410-8.
30. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 1998;14(Suppl B):14B-17B.
31. Jeppesen J, Hein HO, Suadicani P, Gyntelbeg F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97(11):1029-36.
32. Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 1992;70(19):3H-9H.
33. Second Joint Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19(10):1434-503.
34. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998;140(2):199-270.
35. Murchie P, Campbell NC, Ritchie LD, Simpsom JA, Thain J. Secondary prevention clinics for coronary heart disease: Four year follow up of a randomised controlled trial in primary care. BMJ 2003;326:84-90.
36. Ebrahim S, Davey-Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. [Review.] Cochrane Database Syst Rev 2000;(2):CD001561.
37. Pechacek TF, Asma S, Eriksen MP. Tobacco: Global burden and community solutions. In: Yusuf S, Calms A, Camm JA, Fallen EL, Gersh BJ (editors). Evidence based cardiology. London: BMJ Books, 1998;165-78.
38. Post Coronary Artery Bypass Graft (Post-CABG) Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336(3):153-62.
39. Effect of lowering LDL-C beyond currently recommended minimum levels- The Treating to New Targets (TNT) study. 13th International Symposium on Drugs Affecting Lipid Metabolism. Vienna (Austria), 30 May 1998.
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering in 20536 high risk individuals: A randomised controlled clinical trial. Lancet 2002;360:7-22.
41. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
42. Brindle P, Fahey T. Primary prevention of coronary heart disease: Unevaluated screening inhibits informed consent. BMJ 2002;325:56-7.
43. McManus RJ, Mant J, Meulendijks CFM, Salter RA, Pattison HM, Roalfe AK, et al. Coronary heart disease risk estimation in practice: Trial of primary care physicians and nurses using four different CHD risk score calculators in routine primary care settings. BMJ 2002;324:459-64.
44. Ramsay LE, Tang JL, Wright J, Durrington PN, Smith GD. Coronary risk assessment methods and cholesterol lowering. Lancet 1999;353:1095-7.
45. Betteridge DJ, Dodson PM, Durrington PN, Hughes EA, Laker MF, Nicholls DP, et al. Management of hyperlipidaemia: Guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993;69:359-69.
46. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605-13.
47. Herrington DM, Fong J, Sempos CT, Black DM, Schrott HG, Rautaharju P, et al. Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am Heart J 1998;136:115-24.
48. Rich M. Aggressive risk factor management in the elderly: Are you ever too old? Am J Geriatr Cardiol 1999;8:72-9.
49. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160(4):459-67.
50. NCEP. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89(3):1333-445.
51. Witztum JL. Drugs Used in the Treatment of Hyperliproteinemias. 9th ed. New York: McGraw-Hill, 1996.
52. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81(5):582-7.
53. Gotto AM. Contemporary Diagnosis and Management of Lipid Disorders. Newtown (PA): Handbooks in Healthcare, 1999.
54. Fulcher MH, Mathur G. Dyslipidaemia. New Ethicals Journal 1998;21:68-72.
55. Ooi TC, Heinonen T, Alaupovic P, Davignon J, Leiter L, Lupien PJ, et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate. Arterioscler Thromb Vasc Biol 1997;17(9):1793-9.
56. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: An epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
57. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229-34.
58. Dean JD, Durrington PN. Treatment of dyslipoproteinaemia in diabetes mellitus. Diabet Med 1996;13(4):297-312.
59. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
60. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73(14):3D-11D.
61. Carlsson CM, Carnes M, McBride PE, Stein JH. Managing dyslipidemia in older adults. J Am Geriatr Soc 1999;47(12):1458-65.